254 related articles for article (PubMed ID: 26748506)
1. Post-Marketing Benefit-Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis.
Ledent E; Lieftucht A; Buyse H; Sugiyama K; Mckenna M; Holl K
Drug Saf; 2016 Mar; 39(3):219-30. PubMed ID: 26748506
[TBL] [Abstract][Full Text] [Related]
2. Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
Ledent E; Arlegui H; Buyse H; Basile P; Karkada N; Praet N; Nachbaur G
BioDrugs; 2018 Apr; 32(2):139-152. PubMed ID: 29589230
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the potential risks and benefits of infant rotavirus vaccination in England.
Clark A; Jit M; Andrews N; Atchison C; Edmunds WJ; Sanderson C
Vaccine; 2014 Jun; 32(29):3604-10. PubMed ID: 24814524
[TBL] [Abstract][Full Text] [Related]
4. Potential intussusception risk versus health benefits from rotavirus vaccination in Latin America.
Desai R; Parashar UD; Lopman B; de Oliveira LH; Clark AD; Sanderson CF; Tate JE; Matus CR; Andrus JK; Patel MM
Clin Infect Dis; 2012 May; 54(10):1397-405. PubMed ID: 22431803
[TBL] [Abstract][Full Text] [Related]
5. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C
Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466
[TBL] [Abstract][Full Text] [Related]
6. A benefit-risk analysis of rotavirus vaccination, France, 2015.
Lamrani A; Tubert-Bitter P; Hill C; Escolano S
Euro Surveill; 2017 Dec; 22(50):. PubMed ID: 29258644
[TBL] [Abstract][Full Text] [Related]
7. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
Arlegui H; Nachbaur G; Praet N; Bégaud B; Caro JJ
Clin Ther; 2020 Oct; 42(10):1983-1991.e2. PubMed ID: 32988633
[TBL] [Abstract][Full Text] [Related]
8. Value of Post-Licensure Data on Benefits and Risks of Vaccination to Inform Vaccine Policy: The Example of Rotavirus Vaccines.
Parashar UD; Cortese MM; Payne DC; Lopman B; Yen C; Tate JE
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S377-82. PubMed ID: 26590437
[TBL] [Abstract][Full Text] [Related]
9. Sustained reduction in rotavirus-coded hospitalizations in children aged <5 years after introduction of self-financed rotavirus vaccines in Japan.
Kobayashi M; Miyazaki M; Ogawa A; Tatsumi M
Hum Vaccin Immunother; 2020; 16(1):132-137. PubMed ID: 31298962
[TBL] [Abstract][Full Text] [Related]
10. Post-marketing monitoring of intussusception after rotavirus vaccination in Japan.
Bauchau V; Van Holle L; Mahaux O; Holl K; Sugiyama K; Buyse H
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):765-70. PubMed ID: 26013569
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.
Fisman DN; Chan CH; Lowcock E; Naus M; Lee V
Vaccine; 2012 Dec; 30(52):7601-7. PubMed ID: 23107595
[TBL] [Abstract][Full Text] [Related]
12. Analysis of hospitalizations due to intussusception in Sicily in the pre-rotavirus vaccination era (2003-2012).
Costantino C; Restivo V; Cuccia M; Furnari R; Amodio E; Vitale F
Ital J Pediatr; 2015 Aug; 41():52. PubMed ID: 26232152
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico.
Velázquez FR; Colindres RE; Grajales C; Hernández MT; Mercadillo MG; Torres FJ; Cervantes-Apolinar M; DeAntonio-Suarez R; Ortega-Barria E; Blum M; Breuer T; Verstraeten T
Pediatr Infect Dis J; 2012 Jul; 31(7):736-44. PubMed ID: 22695189
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological trends for hospital admissions for acute rotavirus gastroenteritis in Belgium following the introduction of routine rotavirus vaccination and the subsequent switch from lyophilized to liquid formulation of Rotarix™.
Raes M; Strens D; Kleintjens J; Biundo E; Morel T; Vyse A
Epidemiol Infect; 2016 Oct; 144(14):3017-3024. PubMed ID: 27373141
[TBL] [Abstract][Full Text] [Related]
15. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants.
Shui IM; Baggs J; Patel M; Parashar UD; Rett M; Belongia EA; Hambidge SJ; Glanz JM; Klein NP; Weintraub E
JAMA; 2012 Feb; 307(6):598-604. PubMed ID: 22318281
[TBL] [Abstract][Full Text] [Related]
16. Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
Singh T; Delannois F; Haguinet F; Molo LY
Drug Saf; 2022 Feb; 45(2):155-168. PubMed ID: 35015268
[TBL] [Abstract][Full Text] [Related]
17. Rotavirus live, oral, pentavalent vaccine.
Tom-Revzon C
Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
[TBL] [Abstract][Full Text] [Related]
18. Potential intussusception risk versus benefits of rotavirus vaccination in the United States.
Desai R; Cortese MM; Meltzer MI; Shankar M; Tate JE; Yen C; Patel MM; Parashar UD
Pediatr Infect Dis J; 2013 Jan; 32(1):1-7. PubMed ID: 22929172
[TBL] [Abstract][Full Text] [Related]
19. Decline of rotavirus-coded hospitalizations in children under 5 years: A report from Japan where rotavirus vaccines are self-financed.
Kobayashi M; Adachi N; Miyazaki M; Tatsumi M
Vaccine; 2018 May; 36(19):2727-2732. PubMed ID: 29241644
[TBL] [Abstract][Full Text] [Related]
20. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland.
Vesikari T; Uhari M; Renko M; Hemming M; Salminen M; Torcel-Pagnon L; Bricout H; Simondon F
Pediatr Infect Dis J; 2013 Dec; 32(12):1365-73. PubMed ID: 24051998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
